The Role of Sclerostin in Lipid and Glucose Metabolism Disorders

Hewen Jiang, Dijie Li, Ying Han, Nanxi Li, Xiaohui Tao, Jin Liu, Zongkang Zhang, Yuanyuan Yu, Luyao Wang, Sifan Yu, Ning Zhang, Huan Xiao, Xin Yang, Yihao Zhang, Ge Zhang*, Bao-Ting Zhang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Lipid and glucose metabolism are critical for human activities, and their disorders can cause diabetes and obesity, two prevalent metabolic diseases. Studies suggest that the bone involved in lipid and glucose metabolism is emerging as an endocrine organ that regulates systemic metabolism through bone-derived molecules. Sclerostin, a protein mainly produced by osteocytes, has been therapeutically targeted by antibodies for treating osteoporosis owing to its ability to inhibit bone formation. Moreover, recent evidence indicates that sclerostin plays a role in lipid and glucose metabolism disorders. Although the effects of sclerostin on bone have been extensively examined and reviewed, its effects on systemic metabolism have not yet been well summarized. In this paper, we provide a systemic review of the effects of sclerostin on lipid and glucose metabolism based on in vitro and in vivo evidence, summarize the research progress on sclerostin, and prospect its potential manipulation for obesity and diabetes treatment.
Original languageEnglish
Article number115694
JournalBiochemical Pharmacology
Volume215
Early online date21 Jul 2023
DOIs
Publication statusPublished - Sept 2023

Scopus Subject Areas

  • Biochemistry
  • Pharmacology

User-Defined Keywords

  • diabetes
  • glucose metabolism
  • lipid metabolism
  • obesity
  • sclerostin
  • Glucose metabolism
  • Obesity
  • Sclerostin
  • Diabetes
  • Lipid metabolism

Fingerprint

Dive into the research topics of 'The Role of Sclerostin in Lipid and Glucose Metabolism Disorders'. Together they form a unique fingerprint.

Cite this